• Participants with an interest in the field of leprosy are invited to submit abstracts for review and selection for Oral or E-Poster Presentations.
• Abstracts may consist of Research Abstracts (Research Project) or Case Reports in the field of leprosy that have not been previously presented at national or international meetings.
• The abstract must be based on ethical and valid scientific and/or clinical methods.
• Trade names (of drugs and/or equipment) should not be included in the title. If trade names are mentioned within the extended abstract, they should be written after the generic name in the following format: generic name (trade name®).
• Any treatment or substance mentioned in the material must be identified by its scientific name.
• The decision regarding oral or E-poster presentations is at the sole discretion of the committee. This decision is final and cannot be contested.
• Abstracts can be submitted without ILC registration as participants; however, accepted abstracts can only be presented in the conference program once the presenter has provided proof of registration/payment.
• Authors cannot make changes to the abstract once it has been submitted.
• Each participant may submit a maximum of one entry as the main author.
• Selected abstracts cannot be submitted to other scientific publication platforms for a period of 3 months following the announcement of the selected abstracts.
• It is not permitted to submit the related abstract to other scientific publication platforms until the conclusion of ILC 2025.
• Registration fees that have been paid are non-refundable and cannot be canceled.

• Abstracts must be submitted in English. A “blind” selection process will be used.
• The title should not be written entirely in capital letters.
• The size of abstract has a total up to 400 words.
• The submission program will automatically calculate the size of your abstract and will not allow submissions that do not fit in the size requirements.
• Use generic names. The use of commercial drug names, brands and registered trademarks are strictly prohibited. Drugs should be referred to by the active substance or pharmacological designation.
• No mention of pharmaceutical company names should be included in the abstract.

• Oral Presentation :
  • Slides should be in Microsoft PowerPoint format and prepared in English.
  • The presentation language is English.
  • The deadline to submit slides is 30 April 2025, at 3:00 PM WIB.
  • Participants are still required to bring a soft copy during the presentation.
  • PowerPoint files should be submitted with the title " PPT ORAL PRESENTATION PARTICIPANT ILC 2025 (unique code)” for example: " PPT ORAL PRESENTATION PARTICIPANT ILC 2025 RP0015/OP001" through the ilcbali2025.com website. The unique code is obtained once the participant successfully submits the abstract.
• E-Poster :

E-Poster files should be submitted with the title "E-Poster ILC 2025 (unique code)" for example: "E-Poster ILC 2025 RP0015/EP001" through the ilcbali2025.com website. The unique code is obtained once the participant successfully submits the abstract. We do not accept any revisions after the deadline.

1. E-Posters will be displayed on an LCD screen with the following specifications:
   • Language: English
   • Format: JPG (portrait orientation, 1 page)
   • Pixels: 1920 x 1080 pixels
   • Font: minimum size 16
   • File size: 10-20 MB
   • Illustrations, images, or tables should be informative and easy to understand.
   • Does not support video or audio features.
   • Color composition should be harmonious and clear.
2. Presenters are expected to stand next to the LCD screen during the E-Poster presentation. Time and venue will be announced later.
3. Research and Case Report E-Posters must include:
   • Author’s identity, including the main and co-authors, as well as the institution, should be fully listed.
   • The title should be written in uppercase.
4. The total number of references in the E-Poster should not exceed 10.
5. Presenters must bring a soft copy of the E-Poster during the ILC.